Bird‑flu vaccine trial

Messenger RNA vaccines work like a temporary instruction sheet: cells read the code, make one viral protein, and the immune system learns to recognize it. Moderna and its partners have now started a Phase 3 trial of an H5 bird-flu shot in the United States and Britain. (clinicaltrials.gov) (newswire.com) The vaccine candidate is called mRNA-1018, and Moderna said the first participants were dosed on April 21, 2026. The late-stage study is expected to enroll about 4,000 adults age 18 and older in the two countries. (newswire.com) (clinicaltrials.gov) Phase 3 means the shot has moved into large human testing after earlier studies. This trial is designed to measure safety, side effects and whether two doses trigger antibody responses against H5 influenza. (clinicaltrials.gov) Bird flu, or avian influenza, usually spreads in birds, but health agencies track it because some strains can infect people after contact with sick poultry, livestock or contaminated environments. The World Health Organization says sporadic human infections and small clusters can occur wherever these viruses are circulating in animals. (who.int) (cdn.who.int) U.S. officials still rate the public-health risk as low, and the Centers for Disease Control and Prevention says there is no known person-to-person spread from the H5N1 viruses now circulating in birds globally and in U.S. outbreaks. But the virus is also affecting poultry and dairy cattle in the United States, which has kept surveillance and vaccine planning active. (cdc.gov 1) (cdc.gov 2) (aphis.usda.gov) The timing is tight. Cambodia’s health ministry said a 66-year-old woman in Svay Rieng province tested positive for H5N1 on April 21, and local reports described it as the country’s fourth human case of 2026. (en.kampucheathmey.com) (english.news.cn) The World Health Organization’s Western Pacific update published April 17 had listed no new H5N1 cases from April 10 to 16, showing how recently the Cambodia case emerged. That same WHO update said 993 human H5N1 cases had been reported globally from 2003 through January 22, 2026, including 477 deaths. (cdn.who.int) The trial also revives a program that needed new backing. CEPI, the Coalition for Epidemic Preparedness Innovations, said in December 2025 it would invest up to $54.3 million to help push mRNA-1018 toward licensure after the study had been delayed. (newswire.com) (fiercebiotech.com) Moderna said a successful result could support regulatory filings alongside data from its separate seasonal flu vaccine program, mRNA-1010, which the company said is already under review in the United States, the European Union, Canada and Australia. The H5 study’s estimated primary completion date is January 28, 2027. (newswire.com) (clinicaltrials.gov) For now, the trial is not a public vaccination campaign. It is a test of whether an mRNA platform that moved quickly in COVID-19 can also produce a stockpiled bird-flu vaccine before the virus changes into a wider human threat. (clinicaltrials.gov) (cdc.gov)